Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Authors
Keywords
-
Journal
EMBO Molecular Medicine
Volume -, Issue -, Pages -
Publisher
EMBO
Online
2021-05-05
DOI
10.15252/emmm.202114022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
- (2020) Shorena Janelidze et al. NATURE MEDICINE
- Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
- (2020) Thomas K Karikari et al. LANCET NEUROLOGY
- A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease
- (2020) Nicolas R. Barthélemy et al. NATURE MEDICINE
- Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease
- (2020) Sang Su Kwak et al. Nature Communications
- Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
- (2020) Adam S. Fleisher et al. JAMA Neurology
- Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
- (2020) Antoine Leuzy et al. JAMA Neurology
- Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
- (2020) Niklas Mattsson-Carlgren et al. Science Advances
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
- (2020) Sebastian Palmqvist et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
- (2020) Nicolas R. Barthélemy et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
- (2020) Shorena Janelidze et al. JAMA Neurology
- Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
- (2019) Rik Ossenkoppele et al. NEUROLOGY
- Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease
- (2019) Niklas Mattsson et al. Alzheimers & Dementia
- Advances and considerations in AD tau-targeted immunotherapy
- (2019) Alice Bittar et al. NEUROBIOLOGY OF DISEASE
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
- (2018) Harald Hampel et al. Nature Reviews Neurology
- CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
- (2016) Bob Olsson et al. LANCET NEUROLOGY
- Increased CSF A during the very early phase of cerebral A deposition in mouse models
- (2015) L. F. Maia et al. EMBO Molecular Medicine
- Primary age-related tauopathy (PART): a common pathology associated with human aging
- (2014) John F. Crary et al. ACTA NEUROPATHOLOGICA
- The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
- (2014) Reisa Sperling et al. NEURON
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More